Clozapine-induced ERK1 and ERK2 signaling in prefrontal cortex is mediated by the EGF receptor

Journal of Molecular Neuroscience

Volumn 39, Issue 1-2, 2009, Pages 185-198

  Pereira, Avril ^a,b   Fink, George ^a,b   Sundram, Suresh ^a,b,c  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c NORTHERN HOSPITAL   (Australia)

Author keywords

Antipsychotic drug; EGF receptor; ERK; Prefrontal cortex; Schizophrenia; Signal transduction

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 3,5 DI TERT BUTYL ALPHA CYANO 4 HYDROXYTHIOCINNAMAMIDE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; 6,7 DIMETHYL 2 PHENYLQUINOXALINE; ARIPIPRAZOLE; CARBACHOL; CLOZAPINE; EPIDERMAL GROWTH FACTOR RECEPTOR; HALOPERIDOL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PROTEIN TYROSINE KINASE INHIBITOR; QUETIAPINE; RACLOPRIDE; SEROTONIN 2A AGONIST; TYRPHOSTIN A9; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOSE RESPONSE; ENZYME PHOSPHORYLATION; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; PREFRONTAL CORTEX; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM;

ANIMALS; ANTIPSYCHOTIC AGENTS; CELLS, CULTURED; CHOLINERGIC AGENTS; CLOZAPINE; CYCLIC AMP-DEPENDENT PROTEIN KINASES; ENZYME ACTIVATION; ENZYME INHIBITORS; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; HALOPERIDOL; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEURONS; PREFRONTAL CORTEX; RACLOPRIDE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEROTONIN AGENTS; SIGNAL TRANSDUCTION; TYPE C PHOSPHOLIPASES;

MURINAE;

EID: 74149085199     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12031-009-9188-5     Document Type: Article

References (40)

1. Ahmed, M. R., Gurevich, V. V., Dalby, K. N., Benovic, J. L., & Gurevich, E. V. (2008). Haloperidol and clozapine differentially affect the expression of arrestins, receptor kinases, and extracellular signalregulated kinase activation. The Journal of Pharmacology and Experimental Therapeutics, 325, 276-283. doi:10.1124/jpet.107.131987.
2. Anttila, S., Illi, A., Kampman, O., Mattila, K. M., Lehtimaki, T., & Leinonen, E. (2004). Association of EGF polymorphism with schizophrenia in Finnish men. Neuroreport, 15, 1215-1218. doi:10.1097/00001756-200405190- 00027.
3. Bespalov, A., Jongen-Relo, A. L., van Gaalen, M., Harich, S., Schoemaker, H., & Gross, G. (2007). Habituation deficits induced by metabotropic glutamate receptors 2/3 receptor blockade in mice: reversal by antipsychotic drugs. The Journal of Pharmacology and Experimental Therapeutics, 32, 944-950.
4. Britsch, S. (2007). The neuregulin-I/ErbB signaling system in development and disease. Advances in Anatomy, Embryology, and Cell Biology, 190, 1-65. doi:10.1007/978-3-540-37107-6-1.
5. Browning, J. L., Patel, T., Brandt, P. C., Young, K. A., Holcomb, L. A., & Hicks, P. B. (2005). Clozapine and the mitogen-activated protein kinase signal transduction pathway: implications for antipsychotic actions. Biological Psychiatry, 57, 617-623. doi:10.1016/j.biopsych.2004.12.002.
6. Bruins Slot, L. A., De Vries, L., Newman-Tancredi, A., & Cussac, D. (2006). Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signalregulated kinase. European Journal of Pharmacology, 534, 63-70. doi:10.1016/j.ejphar.2006.01.027.
7. Buxbaum, J. D., Georgieva, L., Young, J. J., Plescia, C., Kajiwara, Y., Jiang, Y., et al. (2008). Molecular dissection of NRG1-ERBB4 signaling implicates PTPRZ1 as a potential schizophrenia susceptibility gene. Molecular Psychiatry, 13, 162-172. doi:10.1038/sj.mp. 4001991.
8. Bymaster, F., Perry, K. W., Nelson, D. L., Wong, D. T., Rasmussen, K., Moore, N. A., et al. (1999). Olanzapine: a basic science update. The British Journal of Psychiatry Supplement, 36-40.
9. Cussac, D., Duqueyroix, D., Newman-Tancredi, A., & Millan, M. J. (2002). Stimulation by antipsychotic agents of mitogen-activated protein kinase (MAPK) coupled to cloned, human (h) serotonin (5-HT) (1A) receptors. Psychopharmacology, 162, 168-177. doi:10.1007/s00213-002-1043-0.
10. Dwivedi, Y., Rizavi, H. S., & Pandey, G. N. (2002). Differential effects of haloperidol and clozapine on [(3) H]cAMP binding, protein kinase A (PKA) activity, and mRNA and protein expression of selective regulatory and catalytic subunit isoforms of PKA in rat brain. The Journal of Pharmacology and Experimental Therapeutics, 301, 197-209. doi:10.1124/jpet.301.1.197.
11. Ellis, A. G., Doherty, M. M., Walker, F., Weinstock, J., Nerrie, M., Vitali, A., et al. (2006). Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase. Biochemical Pharmacology, 71, 1422-1434. doi:10.1016/j.bcp. 2006.01.020.
12. Fumagalli, F., Frasca, A., Sparta, M., Drago, F., Racagni, G., & Riva, M. A. (2006). Long-term exposure to the atypical antipsychotic olanzapine differently up-regulates extracellular signal-regulated kinases 1 and 2 phosphorylation in subcellular compartments of rat prefrontal cortex. Molecular Pharmacology, 69, 1366-1372. doi:10.1124/mol.105.019828.
13. Futamura, T., Toyooka, K., Iritani, S., Niizato, K., Nakamura, R., Tsuchiya, K., et al. (2002). Abnormal expression of epidermal growth factor and its receptor in the forebrain and serum of schizophrenic patients. Molecular Psychiatry, 7, 673-682. doi:10.1038/sj.mp. 4001081.
14. Hahn, C. G., Wang, H. Y., Cho, D. S., Talbot, K., Gur, R. E., Berrettini, W. H., et al. (2006). Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nature Medicine, 12, 824-828. doi:10.1038/nm1418.
15. Harrison, P. J., & Law, A. J. (2006). Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biological Psychiatry, 60, 32-140. doi:10.1016/j.biopsych.2005.11.002.
16. Harrison, P. J., & Weinberger, D. R. (2005). Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Molecular Psychiatry, 10, 40-68. doi:10.1038/sj.mp. 4001558.
17. Kamei, H., Nagai, T., Nakano, H., Togan, Y., Takayanagi, M., Takahashi, K., et al. (2006). Repeated methamphetamine treatment impairs recognition memory through a failure of novelty-induced ERK1/2 activation in the prefrontal cortex of mice. Biological Psychiatry, 59, 75-84. doi:10.1016/j.biopsych.2005. 06.006.
18. Kane, J., Honigfeld, G., Singer, J., & Meltzer, H. (1988). Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45, 789-796.
19. Kapur, S., & Seeman, P. (2001). Does fast dissociation from the dopamine D (2) receptor explain the action of atypical antipsychotics?: A new hypothesis. The American Journal of Psychiatry, 158, 360-369. doi:10.1176/appi.ajp. 158.3.360.
20. Kornhuber, J., Schultz, A., Wiltfang, J., Meineke, I., Gleiter, C. H., Zochling, R., et al. (1999). Persistence of haloperidol in human brain tissue. The American Journal of Psychiatry, 156, 885-890.
21. Lewis, S. W., Barnes, T. R., Davies, L., Murray, R. M., Dunn, G., Hayhurst, K. P., et al. (2006). Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophrenia Bulletin, 32, 715-723. doi:10.1093/schbul/sbj067.
22. Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England Journal of Medicine, 353, 1209-1223. doi:10.1056/NEJMoa051688.
23. Lu, X. H., & Dwyer, D. S. (2005). Second-generation antipsychotic drugs, olanzapine, quetiapine, and clozapine enhance neurite outgrowth in PC12 cells via PI3K/AKT, ERK, and pertussis toxin-sensitive pathways. Journal of Molecular Neuroscience, 27, 43-64. doi:10.1385/JMN:27:1:043.
24. Lu, X. H., Bradley, R. J., & Dwyer, D. S. (2004). Olanzapine produces trophic effects in vitro and stimulates phosphorylation of Akt/PKB, ERK1/2, and the mitogen-activated protein kinase p38. Brain Research, 1011, 58-68. doi:10.1016/j.brainres.2004.03.018.
25. McEvoy, J. P., Lieberman, J. A., Stroup, T. S., Davis, S. M., Meltzer, H. Y., Rosenheck, R. A., et al. (2006). Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. The American Journal of Psychiatry, 163, 600-610. doi:10.1176/appi.ajp. 163.4.600.
26. Meltzer, H. Y. (2004). What's atypical about atypical antipsychotic drugs? Current Opinion in Pharmacology, 4, 53-57. doi:10.1016/j.coph. 2003.09.010.
27. Pozzi, L., Hakansson, K., Usiello, A., Borgkvist, A., Lindskog, M., Greengard, P., et al. (2003). Opposite regulation by typical and atypical anti-psychotics of ERK1/2, CREB and Elk-1 phosphorylation in mouse dorsal striatum. Journal of Neurochemistry, 86, 451-459. doi:10.1046/j.1471- 4159.2003.01851.x.
28. Prenzel, N., Zwick, E., Daub, H., Leserer, M., Abraham, R., Wallasch, C., et al. (1999). EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature, 402, 884-888.
29. Stefansson, H., Sigurdsson, E., Steinthorsdottir, V., Bjornsdottir, S., Sigmundsson, T., Ghosh, S., et al. (2002). Neuregulin 1 and susceptibility to schizophrenia. American Journal of Human Genetics, 71, 877-892. doi:10.1086/342734.
30. Sundram, S., Joyce, P. R., & Kennedy, M. A. (2003). Schizophrenia and bipolar affective disorder: perspectives for the development of therapeutics. Current Molecular Medicine, 3, 393-407. doi:10.2174/1566524033479708.
31. Thomas, G. M., & Huganir, R. L. (2004). MAPK cascade signaling and synaptic plasticity. Nature Reviews. Neuroscience, 5, 173-183. doi:10.1038/nrn1346.
32. Turalba, A. V., Leite-Morris, K. A., & Kaplan, G. B. (2004). Antipsychotics regulate cyclic AMP-dependent protein kinase and phosphorylated cyclic AMP response element-binding protein in striatal and cortical brain regions in mice. Neuroscience Letters, 357, 53-57. doi:10.1016/j.neulet. 2003.11.059.
33. Urban, J. D., Clarke, W. P., von Zastrow, M., Nichols, D. E., Kobilka, B. K., Weinstein, H., et al. (2007). Functional selectivity and classical concepts of quantitative pharmacology. The Journal of Pharmacology and Experimental Therapeutics, 320, 1-13. doi:10.1124/jpet.106.104463.
34. Vanhoose, A. M., Emery, M., Jimenez, L., & Winder, D. G. (2002). ERK activation by G-protein-coupled receptors in mouse brain is receptor identity-specific. The Journal of Biological Chemistry, 277, 9049-9053. doi:10.1074/jbc. M108309200.
35. Waters, C., Pyne, S., & Pyne, N. J. (2004). The role of G-protein coupled receptors and associated proteins in receptor tyrosine kinase signal transduction.. Seminars in Cell & Developmental Biology, 15, 309-323. doi:10.1016/j.semcdb.2003.12.020.
36. Weigmann, H., Hartter, S., Fischer, V., Dahmen, N., & Hiemke, C. (1999). Distribution of clozapine and desmethylclozapine between blood and brain in rats. European Neuropsychopharmacology, 9, 253-256. doi:10.1016/S0924-977X (98) 00036-4.
37. White, A. R., Zheng, H., Galatis, D., Maher, F., Hesse, L., Multhaup, G., et al. (1998). Survival of cultured neurons from amyloid precursor protein knock-out mice against Alzheimer's amyloid-beta toxicity and oxidative stress. The Journal of Neuroscience, 18, 6207-6217.
38. Wong, R. W., & Guillaud, L. (2004). The role of epidermal growth factor and its receptors in mammalian CNS. Cytokine & Growth Factor Reviews, 15, 147-156. doi:10.1016/j.cytogfr. 2004.01.004.
39. Yan, B., He, J., Xu, H., Zhang, Y., Bi, X., Thakur, S., et al. (2007). Quetiapine attenuates the depressive and anxiolytic-like behavioural changes induced by global cerebral ischemia in mice. Behavioural Brain Research, 182, 36-41. doi:10.1016/j. bbr.2007.05.002.
40. Zocchi, A., Fabbri, D., & Heidbreder, C. A. (2005). Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex. Neuroscience Letters, 387, 157-161.